Comparison of predicted AMIO drug interactions versus observed clinical DDIs for drugs primarily metabolized by CYP1A2, CYP2C9, CYP2D6, or CYP3A4
Predicted interactions are based on the sum of [I]u/Ki,u data (eq. 1) determined for the reversible inhibition of specific P450 substrate probes by AMIO and its circulating human metabolites (Table 1).
| Pharmaceutical | In Vivo DDI (AUCi/AUC) | Predicted DDI | |||
|---|---|---|---|---|---|
| CYP1A2 | CYP2C9 | CYP2D6 | CYP3A4 | ||
| Lidocaine | 1.21 (Ha et al., 1996) | 1.28 | |||
| S-Warfarin | 2.10 (O’Reilly et al., 1987) | 1.89 | |||
| Metoprolol | 1.94 (Werner et al., 2004) | 1.64 | |||
| Simvastatin | 1.76 (Becquemont et al., 2007) | 1.35 | |||
| R-Warfarin | 1.62 (O’Reilly et al., 1987) | 1.35 | |||
AUC, area under the time versus plasma drug concentration curve.